Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

ClinicalTrials.gov ID: NCT02325791

Public ClinicalTrials.gov record NCT02325791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.

Study identification

NCT ID
NCT02325791
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
1,177 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 6 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2015 (Type not available)
Primary completion
Jul 5, 2017 (Actual)
Completion
Sep 26, 2017 (Actual)
Last update posted
Nov 6, 2018

2015 – 2017

United States locations

U.S. sites
107
U.S. states
36
U.S. cities
107
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama — —
Regeneron Study Site Mobile Alabama — —
Regeneron Study Site Little Rock Arkansas — —
Regeneron Study Site Anaheim California — —
Regeneron Study Site Bell Gardens California — —
Regeneron Study Site Dinuba California — —
Regeneron Study Site Downey California — —
Regeneron Study Site Huntington Beach California — —
Regeneron Study Site La Puente California — —
Regeneron Study Site Los Angeles California — —
Regeneron Study Site Madera California — —
Regeneron Study Site Palmdale California — —
Regeneron Study Site Ventura California — —
Regeneron Study Site West Covina California — —
Regeneron Study Site Aurora Colorado — —
Regeneron Study Site Thornton Colorado — —
Regeneron Study Site Hartford Connecticut — —
Regeneron Study Site Boynton Beach Florida — —
Regeneron Study Site Gainesville Florida — —
Regeneron Study Site Jacksonville Florida — —
Regeneron Study Site Miami Florida — —
Regeneron Study Site Orlando Florida — —
Regeneron Study Site Pensacola Florida — —
Regeneron Study Site Tampa Florida — —
Regeneron Study Site Winter Park Florida — —
Regeneron Study Site Atlanta Georgia — —
Regeneron Study Site Columbus Georgia — —
Regeneron Study Site Dalton Georgia — —
Regeneron Study Site Meridian Idaho — —
Regeneron Study Site Nampa Idaho — —
Regeneron Study Site Peoria Illinois — —
Regeneron Study Site South Bend Indiana — —
Regeneron Study Site Hutchinson Kansas — —
Regeneron Study Site Topeka Kansas — —
Regeneron Study Site Bardstown Kentucky — —
Regeneron Study Site Louisville Kentucky — —
Regeneron Study Site Metairie Louisiana — —
Regeneron Study Site New Orleans Louisiana — —
Regeneron Study Site Shreveport Louisiana — —
Regeneron Study Site Baltimore Maryland — —
Regeneron Study Site Silver Spring Maryland — —
Regeneron Study Site Fall River Massachusetts — —
Regeneron Study Site Woburn Massachusetts — —
Regeneron Study Site Stevensville Michigan — —
Regeneron Study Site Duluth Minnesota — —
Regeneron Study Site Minneapolis Minnesota — —
Regeneron Study Site Saint Paul Minnesota — —
Regeneron Study Site Jackson Mississippi — —
Regeneron Study Site Bridgeton Missouri — —
Regeneron Study Site Kansas City Missouri — —
Regeneron Study Site Lincoln Nebraska — —
Regeneron Study Site Norfolk Nebraska — —
Regeneron Study Site Omaha Nebraska — —
Regeneron Study Site Reno Nevada — —
Regeneron Study Site Lebanon New Hampshire — —
Regeneron Study Site Neptune City New Jersey — —
Regeneron Study Site New Brunswick New Jersey — —
Regeneron Study Site Brooklyn New York — —
Regeneron Study Site Mineola New York — —
Regeneron Study Site New Hyde Park New York — —
Regeneron Study Site New York New York — —
Regeneron Study Site Rochester New York — —
Regeneron Study Site Syracuse New York — —
Regeneron Study Site The Bronx New York — —
Regeneron Study Site Boone North Carolina — —
Regeneron Study Site Chapel Hill North Carolina — —
Regeneron Study Site Durham North Carolina — —
Regeneron Study Site Raleigh North Carolina — —
Regeneron Study Site Cincinnati Ohio — —
Regeneron Study Site Cleveland Ohio — —
Regeneron Study Site Columbus Ohio — —
Regeneron Study Site Dayton Ohio — —
Regeneron Study Site Fairfield Ohio — —
Regeneron Study Site Mayfield Heights Ohio — —
Regeneron Study Site Toledo Ohio — —
Regeneron Study Site Youngstown Ohio — —
Regeneron Study Site Oklahoma City Oklahoma — —
Regeneron Study Site Tulsa Oklahoma — —
Regeneron Study Site Gresham Oregon — —
Regeneron Study Site Allentown Pennsylvania — —
Regeneron Study Site Erie Pennsylvania — —
Regeneron Study Site Hermitage Pennsylvania — —
Regeneron Study Site Charleston South Carolina — —
Regeneron Study Site Cheraw South Carolina — —
Regeneron Study Site Greenville South Carolina — —
Regeneron Study Site North Charleston South Carolina — —
Regeneron Study Site Alcoa Tennessee — —
Regeneron Study Site Kingsport Tennessee — —
Regeneron Study Site Nashville Tennessee — —
Regeneron Study Site Austin Texas — —
Regeneron Study Site Fort Sam Houston Texas — —
Regeneron Study Site Houston Texas — —
Regeneron Study Site San Antonio Texas — —
Regeneron Study Site Layton Utah — —
Regeneron Study Site Roy Utah — —
Regeneron Study Site St. George Utah — —
Regeneron Study Site Syracuse Utah — —
Regeneron Study Site Charlottesville Virginia — —
Regeneron Study Site Midlothian Virginia — —
Regeneron Study Site Richmond Virginia — —
Regeneron Study Site Vienna Virginia — —
Regeneron Study Site Huntington West Virginia — —
Regeneron Study Site Kingwood West Virginia — —
Regeneron Study Site Morgantown West Virginia — —
Regeneron Study Site Madison Wisconsin — —
Regeneron Study Site Marshfield Wisconsin — —
Regeneron Study Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02325791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2018 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02325791 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →